Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection

Remdesivir (RDV) is a nucleotide analog prodrug with demonstrated clinical benefit in patients with coronavirus disease 2019 (COVID-19). In October 2020, the US FDA approved intravenous (IV) RDV as the first treatment for hospitalized COVID-19 patients. Furthermore, RDV has been approved or authoriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermillion, Meghan S., Murakami, Eisuke, Ma, Bin, Pitts, Jared, Tomkinson, Adrian, Rautiola, Davin, Babusis, Darius, Irshad, Hammad, Siegel, Dustin, Kim, Cynthia, Zhao, Xiaofeng, Niu, Congrong, Yang, Jesse, Gigliotti, Andrew, Kadrichu, Nani, Bilello, John P., Ellis, Scott, Bannister, Roy, Subramanian, Raju, Smith, Bill, Mackman, Richard L., Lee, William A., Kuehl, Philip J., Hartke, Jim, Cihlar, Tomas, Porter, Danielle P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961622/
https://www.ncbi.nlm.nih.gov/pubmed/34968150
http://dx.doi.org/10.1126/scitranslmed.abl8282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961622/
https://www.ncbi.nlm.nih.gov/pubmed/34968150
http://dx.doi.org/10.1126/scitranslmed.abl8282

Ejemplares similares